Paper42908038PubMed
Pregnancy outcome after first-trimester exposure to JAK inhibitors - an evaluation of the German Embryotox cohort.
Habbel AS and 3 others. BMC Pharmacol Toxicol, 2026.
Cite this record
ConductScience Library. Pregnancy outcome after first-trimester exposure to JAK inhibitors - an evaluation of the German Embryotox cohort. Papers, record 42908038. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42908038
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pregnancy outcome after first-trimester exposure to JAK inhibitors - an evaluation of the German Embryotox cohort.
- Journal
- BMC Pharmacol Toxicol
- Year
- 2026
- Publication types
- Journal Article, Observational Study
- Revised in PubMed
- 2026-10-26
Source PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Pregnancy Outcome | Major topic |
| Janus Kinase Inhibitors | Major topic |
| Abnormalities, Drug-Induced | Major topic |
| Humans | |
| Female | |
| Pregnancy | |
| Germany | |
| Pregnancy Trimester, First | |
| Adult | |
| Cohort Studies |
Source PubMed
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40370416 | Upadacitinib as Rescue Therapy in a Pregnant Patient With IBD. | ACG Case Rep J | 2025 | https://conductscience.org/library/papers/40370416 | PubMed |
| 2 | 39008024 | Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports. | Drug Saf | 2024 | https://conductscience.org/library/papers/39008024 | PubMed |
| 3 | 39626694 | Prevalence, Incidence, and Age at Diagnosis of Boys With Hypospadias: A Nationwide Population-Based Epidemiological Study. | J Urol | 2025 | https://conductscience.org/library/papers/39626694 | PubMed |
| 4 | 38591862 | Tofacitinib as a Rescue Therapy for Ulcerative Colitis in Pregnancy. | Inflamm Bowel Dis | 2024 | https://conductscience.org/library/papers/38591862 | PubMed |
| 5 | 31972425 | The role of JAK/STAT signaling pathway and its inhibitors in diseases. | Int Immunopharmacol | 2020 | https://conductscience.org/library/papers/31972425 | PubMed |
| 6 | 38317692 | Normal Infant Immunologic Assessment and Uneventful Live Rotavirus Vaccination Despite Continuous Tofacitinib Exposure In Utero and During Breastfeeding. | Crohns Colitis 360 | 2024 | https://conductscience.org/library/papers/38317692 | PubMed |
| 7 | 33915094 | Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. | Lancet | 2021 | https://conductscience.org/library/papers/33915094 | PubMed |
| 8 | 37208335 | Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37208335 | PubMed |
| 9 | 38202041 | Reproductive Safety Issues of Novel Small Molecules for the Treatment of Inflammatory Bowel Disease: A Systematic Review. | J Clin Med | 2023 | https://conductscience.org/library/papers/38202041 | PubMed |
| 10 | 41305879 | Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in VigiBase. | Clin Transl Sci | 2025 | https://conductscience.org/library/papers/41305879 | PubMed |
| 11 | 37795665 | Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis. | J Eur Acad Dermatol Venereol | 2024 | https://conductscience.org/library/papers/37795665 | PubMed |
| 12 | 34874264 | Pregnancy and Autoimmune Disease. | Dtsch Arztebl Int | 2022 | https://conductscience.org/library/papers/34874264 | PubMed |
| 13 | 29063150 | Drug safety in pregnancy: the German Embryotox institute. | Eur J Clin Pharmacol | 2018 | https://conductscience.org/library/papers/29063150 | PubMed |
| 14 | 38309493 | Tofacitinib in Pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood, and Breast Milk Concentrations. | Clin Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/38309493 | PubMed |
| 15 | 41486192 | Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications. | Nat Rev Drug Discov | 2026 | https://conductscience.org/library/papers/41486192 | PubMed |
| 16 | 25644395 | Does the average drug exposure in pregnant women affect pregnancy outcome? A comparison of two approaches to estimate the baseline risks of adverse pregnancy outcome. | Pharmacoepidemiol Drug Saf | 2015 | https://conductscience.org/library/papers/25644395 | PubMed |
| 17 | 38970379 | Use of Upadacitinib as Salvage Therapy for Ulcerative Colitis in Pregnancy: A Case Report. | Inflamm Bowel Dis | 2025 | https://conductscience.org/library/papers/38970379 | PubMed |
| 18 | 41002213 | Pregnancy Outcomes After Maternal or Paternal Exposure to Tofacitinib Across Clinical Programs. | Am J Gastroenterol | 2026 | https://conductscience.org/library/papers/41002213 | PubMed |
| 19 | 34824210 | The JAK/STAT signaling pathway: from bench to clinic. | Signal Transduct Target Ther | 2021 | https://conductscience.org/library/papers/34824210 | PubMed |
| 20 | 34309233 | Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report. | Birth Defects Res | 2021 | https://conductscience.org/library/papers/34309233 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42908038
GET https://conductscience.org/api/papers/v1/42908038/references?page=2